# Expanded Access to Diagnostic Imaging for Staging of Recurrent Prostate Cancer

> **NCT02260817** · PHASE3 · COMPLETED · sponsor: **Global Isotopes, LLC d/b/a Zevacor Molecular** · enrollment: 109 (actual)

## Conditions studied

- Metastatic Prostate Cancer

## Interventions

- **DRUG:** 11C-choline Injection

## Key facts

- **NCT ID:** NCT02260817
- **Lead sponsor:** Global Isotopes, LLC d/b/a Zevacor Molecular
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10
- **Primary completion:** 2016-06
- **Final completion:** 2018-06
- **Target enrollment:** 109 (ACTUAL)
- **Last updated:** 2019-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02260817

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02260817, "Expanded Access to Diagnostic Imaging for Staging of Recurrent Prostate Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02260817. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*